Product Description
Novelogics is a privately-held, preclinical stage biotech company developing a novel monoclonal antibody immunotherapy drug for the treatment of cancer. The company is based in Vancouver, Canada. Our antibody drug interacts with target proteins known to be immune suppressive and which function to reduce the ability of the immune system to detect and destroy unwanted cancer cells. This drug target is found in multiple deadly cancer types including solid tumors, blood cancers and in other diseases, thereby implying that the potential market for our drug is large. Novelogics’ innovative therapeutic approach restores immune responses against cancer cells and is expected to treat cancer patients in a safer fashion while maintaining their quality of life. (Sourced from: https://www.linkedin.com/company/novelogics/?originalSubdomain=ca)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novelogics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|